This Week in the Medical JournalsGenomeWebAlso in Lancet Oncology, a second team of MD Anderson researchers collaborated with researchers from New Jersey and Puerto Rico in a trial of rituximab combined with lenalidomide to treat relapsed or refractory…
Patients With Serious Kidney Disorder Get Help With Immune DrugRedOrbitPatients with a particular kidney immune disorder experienced remission when taking the immune drug rituximab, even when standard therapies had failed. Rituximab was safe and well-t…
Immune drugs helps with kidney disorderCBS42Idiopathic membranous nephropathy (IMN) can eventually lead to kidney failure. Standard therapies for IMN can be toxic and lead to further complications, but a new study has discovered the drug rituximab whic…
Sclerosi Multipla: uno studio canadese smentisce l'efficacia dell'interferone beta …informazione.it (Comunicati Stampa)Biogen Idec e Abbott annunciano i risultati positivi della prima sperimentazione per la registrazione di Daclizumab HYP nel…
Immune drug helps patients with serious kidney disorderEurekAlert (press release)Patients with a particular kidney immune disorder experienced remission when taking the immune drug rituximab, even when standard therapies had failed. Rituximab was safe …
OIG faults noncompliant drug billing for Medicare overpaymentsFierceHealthcareJohnston Memorial Hospital in Abingdon, Va., did not follow federal rules in billing Medicare for 31 reviewed items involving drug injections (doxorubicin hydrochloride lipos…
Abbott Laboratories Management Discusses Q2 2012 Results – Earnings Call …Seeking AlphaDaclizumab is a next-generation biologic for MS, currently in late-stage development with a partner company. Results from the Phase III study are expected in 2014….
el periodicBelenguer afirma que las nuevas terapias biológicas son más eficaces en el …el periodic… dos de las nuevas terapias biológicas: los agentes orales (Fingolimod, Dimetil Fumarato, Laquinimod y Teriflunomida); y los anticuerpos monoclona…
Abbott Reports Strong Second Quarter ResultsEquities.comAbbott is partnering on the development of a novel, next-generation antibody, daclizumab, which is currently in Phase 3 clinical trials for MS. Additionally, Abbott recently announced positive res…
RTT NewsAbbott Beats on EPS, Affirms View – Analyst BlogNASDAQAbbott Labs, along with partner Biogen ( BIIB ), is evaluating daclizumab in a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRMS). Abbott Labs is also working…